申请人:Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
公开号:US10662174B2
公开(公告)日:2020-05-26
Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).
本文提供了一系列 BTK 抑制剂,特别公开了由式 (I)、(II)、(III) 或 (IV) 表示的化合物、其药学上可接受的盐、同系物或其原药。